Literature DB >> 24519201

Factors associated with thrombocytopenia in severe leptospirosis (Weil's disease).

Elizabeth F Daher1, Geraldo B Silva1, Charles O Silveira1, Felipe S Falcão1, Marília P Alves1, Jório A A A Mota1, Joyce B Lima1, Rosa M S Mota2, Ana Patrícia F Vieira1, Roberto da Justa Pires3, Alexandre B Libório1.   

Abstract

OBJECTIVE: This study was conducted to investigate factors associated with thrombocytopenia in a large cohort of patients with leptospirosis in an endemic area.
METHODS: This retrospective study included 374 consecutive patients with leptospirosis who were admitted to tertiary hospitals in Fortaleza, Brazil. All patients had a diagnosis of severe leptospirosis (Weil's disease). Acute kidney injury was defined according to the RIFLE criteria. Thrombocytopenia was defined as a platelet count <100,000/mm3.
RESULTS: A total of 374 patients were included, with a mean age of 36.1 ± 15.5 years, and 83.4% were male. Thrombocytopenia was present at the time of hospital admission in 200 cases (53.5%), and it developed during the hospital stay in 150 cases (40.3%). The patients with thrombocytopenia had higher frequencies of dehydration (53% vs. 35.3%, p=0.001), epistaxis (5.7% vs. 0.8%, p=0.033), hematemesis (13% vs. 4.6%, p=0.006), myalgia (91.5% vs. 84.5%, p=0.038), hematuria (54.8% vs. 37.6%, p=0.011), metabolic acidosis (18% vs. 9.2%, p=0.016) and hypoalbuminemia (17.8% vs. 7.5%, p=0.005). The independent risk factors associated with thrombocytopenia during the hospital stay were lengthy disease (OR: 1.2, p=0.001) and acute kidney injury (OR: 6.6, p=0.004). Mortality was not associated with thrombocytopenia at admission (12.5% vs. 12.6%, p=1.000) or during the hospital stay (12.6% vs. 11.3%, p=0.748).
CONCLUSIONS: Thrombocytopenia is a frequent complication in leptospirosis, and this condition was present in more than half of patients at the time of hospital admission. Lengthy disease and acute kidney injury are risk factors for thrombocytopenia. There was no significant association between thrombocytopenia and mortality.

Entities:  

Mesh:

Year:  2014        PMID: 24519201      PMCID: PMC3912336          DOI: 10.6061/clinics/2014(02)06

Source DB:  PubMed          Journal:  Clinics (Sao Paulo)        ISSN: 1807-5932            Impact factor:   2.365


INTRODUCTION

Leptospirosis is an infectious disease caused by the pathogenic spirochete Leptospira interrogans, which has a worldwide distribution 1-3. There is a large range of clinical manifestations in leptospirosis, and infected people can present with asymptomatic illness, self-limited systemic infection or severe and potentially fatal disease 1-5. Symptomatic disease begins suddenly, with headache, fever, malaise, myalgia, conjunctival suffusion and transient rash 1. The severe form is characterized by jaundice, acute kidney injury (AKI) and hemorrhage, known as Weil's disease, and is mainly caused by the serovars Icterohaemorrhagiae, Copenhageni and Lai. There are also severe forms of the disease that occur without jaundice or renal failure, such as hemorrhagic pneumonitis 1,2. Hematological manifestations are common in leptospirosis and are usually manifested as thrombocytopenia 6-8. Thrombocytopenia is often observed in connection with hemorrhagic pneumopathy and is a significant predictor of the development of acute respiratory failure, which is currently the main cause of death in this disease 6,7,9. The aim of this study was to investigate the factors associated with thrombocytopenia in a large cohort of patients with severe leptospirosis in an endemic area.

PATIENTS AND METHODS

We examined a retrospective cohort of 374 consecutive patients admitted to tertiary hospitals in Fortaleza, northeastern Brazil. All patients had a diagnosis of leptospirosis confirmed by a microscopic agglutination test (MAT), with titers equal to or higher than 1∶800. Serological testing was performed at least 7 days after admission, and patients with titers lower than 1∶800 were excluded. Patients with negative serologies or other comorbidities, such as hypertension, diabetes and autoimmune diseases, were not included. The protocol of this study was approved by the ethics committees of both institutions. Demographic characteristics, such as age, gender, the time between the onset of the initial symptoms and hospital admission and the length of hospital stay, were recorded. The clinical investigation included a record of all clinical signs and symptoms presented by each patient at hospital admission and during the hospital stay. Hemorrhagic phenomena, such as gastrointestinal hemorrhage, hemoptysis or blood-tinged sputum, hematuria and epistaxis, were recorded at admission and during hospitalization. Laboratory data collected during the hospital stay included an assessment of serum urea, creatinine, sodium, potassium, bilirubin, aspartate aminotransaminase (AST), alanine aminotransaminase (ALT), creatine kinase and lactate dehydrogenase levels; the total blood count; and the prothrombin time (PT). Respiratory failure was defined as a need for mechanical ventilation. AKI was defined according to the RIFLE criteria 10. Thrombocytopenia was defined as a platelet count <100,000/mm3, and severe thrombocytopenia was defined as a count <50,000/mm3. The occurrence of metabolic acidosis was diagnosed at a pH <7.35 and HCO3 <20 mEq/L. Oliguria was defined as a urine volume <400 mL/day after 24 h of effective hydration. Hypotension was defined as a mean arterial blood pressure (MAP) <60 mmHg, and therapy with vasoactive drugs was initiated when the MAP remained <60 mmHg. The systolic blood pressure (SBP) and diastolic blood pressure (DBP) at admission were also analyzed. Dialysis was indicated in those patients who remained oliguric after effective hydration, in those cases in which uremia was associated with hemorrhagic or severe respiratory failure and in those patients with hyperkalemia or metabolic acidosis that was refractory to clinical treatment. The use of antibiotic therapy in the later phase of leptospirosis is still controversial, but penicillin G was administered to several patients, at the discretion of the assistant, at a dosage of 8 million units/day in the first 7-10 days after the patients were admitted.

RESULTS

The patients were divided into two groups according to their platelet levels (with thrombocytopenia vs. without thrombocytopenia). A comparison of clinical and laboratory characteristics was performed to investigate the differences between the two groups. All data were analyzed with the program SPSS ver. 10.0 (Chicago, IL, USA). The comparison of parameters was performed with a Student's t-test and Fisher's exact test. The Mann-Whitney U-test was used for the parameters with a non-normal distribution. A logistic regression model was used for the quantitative variables. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. A multivariate logistic regression was performed to analyze the possible risk factors associated with thrombocytopenia and death. The factors included in the multivariate model were those that showed significance (p<0.05) in the univariate analysis. The patients' mean age was 36.1±15.5 years, and 312 (83.4%) were male. The time between the onset of symptoms and hospital admission was 4.4±3.8 days for patients with thrombocytopenia and 5.9±4.8 days for patients without thrombocytopenia (p = 0.001). The average length of hospital stay was 10.3±6.9 days for patients with thrombocytopenia and 9.3±6.2 days for patients without thrombocytopenia (p = 0.190). The main signs and symptoms presented at admission were fever (96%), myalgia (88.2%), jaundice (78.9%), calf pain (74.2%), headache (72.2%), vomiting (68.2%), asthenia (55.8%), anorexia (50.7%), chills (49.2%), coluria (47.8%), hematuria (47.1%), abdominal pain (46.6%), dehydration (44.8%), diarrhea (41.2%), hepatomegaly (28.9%) and oliguria (21.2%). Thrombocytopenia was present at hospital admission in 200 cases (53.5%), and 150 (40.3%) patients developed this condition during their hospital stay. Severe thrombocytopenia (<50,000/mm3) was found in 107 patients (29.3%). Patients with thrombocytopenia at admission had higher frequencies of dehydration (53% vs. 35.3%, p = 0.001), epistaxis (5.7% vs. 0.8%, p = 0.033), hematemesis (13% vs. 4.6%, p = 0.006), myalgia (91.5% vs. 84.5%, p = 0.038), hematuria (54.8% vs. 37.6%, p = 0.011), metabolic acidosis (18% vs. 9.2%, p = 0.016) and hypoalbuminemia (17.8% vs. 7.5%, p = 0.005). The frequency of oliguria was not higher in patients with thrombocytopenia (23.1% vs. 19.0%, p = 0.374). Penicillin use had a tendency to be more frequent in patients without thrombocytopenia at admission (42.6% vs. 32%, p = 0.07). These data are summarized in Table 1.
Table 1

Comparison of the demographics and clinical manifestations of leptospirosis patients with and without thrombocytopenia at admission.

ThrombocytopeniaNo thrombocytopeniap-value
(N = 200)(N  =  174)
Age36.4±16.336.7±15.00.624
(9-82 years)(9-84 years)
Gender
    Male168 (84.0%)144 (82.8%)0.781
    Female32 (16.0%)30 (17.2%)
    Length of hospital stay10.3±6.99.3±6.20.190
Signs and symptoms
    Crackles33 (16.5%)28 (16.1%)1.000
    Coluria56 (45.5%)64 (50%)0.528
    Dehydration106 (53.0%)61 (35.3%)0.001
    Diarrhea79 (39.5%)75 (43.1%)0.528
    Dyspnea23 (11.7%)16 (9.2%)0.499
    Epistaxis7 (5.7%)1 (0.8%)0.033
    Fever194 (97.0%)165 (94.8%)0.304
    Headache147 (73.5%)123 (70.7%)0.565
    Hematemesis26 (13.0%)8 (4.6%)0.006
    Hematuria69 (54.8%)38 (37.6%)0.011
    Hepatomegaly65 (32.5%)43 (24.7%)0.110
    Hypotension13 (10.6%)14 (10.9%)1.000
    Jaundice164 (82.0%)131 (75.3%)0.128
    Myalgia183 (91.5%)147 (84.5%)0.038
    Tachypnea49 (24.5%)32 (18.4%)0.167
    Vomiting144 (72.0%)111 (63.8%)0.096
    Anorexia80 (53.7%)65 (47.4%)0.344
    Asthenia66 (53.7%)74 (57.8%)0.527
    Oliguria33 (19.0%)46 (23.1%)0.374
    Calf pain106 (78.5%)78 (69.0%)0.109
    Abdominal pain57 (46.3%)60 (46.9%)1.000
Metabolic acidosis36 (18.0%)16 (9.2%)0.016
Hypoalbuminemia35 (17.8%)13 (7.5%)0.005
AKI167(83.9%)134 (77.5%)0.145
Need for dialysis73 (36.5%)51 (29.3%)0.153
Penicillin G use49 (32.0%)52 (42.6%)0.079
Death25 (12.5%)22 (12.6%)1.000

The data are shown as the mean±SD and range (minimum-maximum) or as numbers with percentages in parentheses. Significance, p<0.05. Student's t-test and Fisher's exact test.

Regarding the laboratory data, patients with thrombocytopenia at admission presented with hypokalemia (3.2±0.6 vs. 3.5±0.6 mEq/L, p<0.0001), hypoalbuminemia (2.9±0.6 vs. 3.2±0.6 g/dL, p = 0.067), low hemoglobin levels (10.7±2.0 vs. 11.2±2.1 g/dL, p = 0.021) and high total bilirubin levels (12.3±11.0 vs. 7.5±9.1 mg/dL, p = 0.001) significantly more often than did patients with normal platelet levels (Table 2).
Table 2

Comparison of laboratory data between leptospirosis patients with and without thrombocytopenia at admission.

ThrombocytopeniaNo thrombocytopeniap-value
(N = 200)(N = 174)
Urea at admission (mg/dL)134.9±88.7126.1±94.70.169
(19-578)(15-449)
Creatinine at admission (mg/dL)4.1±2.84.2±3.00.953
(0.3-15.2)(0.2-13.0)
Sodium at admission (mEq/L)132.5±6.5133.8±5.70.164
(114-158)(118-149)
Potassium at admission(mEq/L)3.8±0.94.0±1.00.098
(2.0-8.2)(2.4-8.6)
Potassium min (mEq/L)3.2±0.63.5±0.6<0.0001
(0.5-5.3)(2.0 – 4.8)
Creatine kinase at admission (UI/L)976±3032.1252.2±5110.092
(3-19692.0)(12.0-1978)
Total bilirubin at admission (g/dL)12.3±11.07.5±9.10.001
(0.6-49.5)(0.1-32.7)
Albumin at admission (g/dL)2.9±0.63.2±0.60.067
(1.7-4.4)(2.0-4.3)
AST at admission (UI/L)123±106149.8±4200.078
(23-604)(9-4215)
ALT at admission (UI/L)77.2±90.681.1±85.10.871
(11-956)(8-734)
Hb at admission (g/dL)10.7±2.011.2±2.10.021
(4.4-15.7)(6.8-11.2)
HCO3- at admission (mEq/L)18.8±4.719.5±5.30.375
(8.9-18.2)(9.0-20.2)
TAP (%)74.6±22.874.7±18.90.284
(17.3-100)(35.5-100)

The data are shown as the mean ± SD and range (minimum-maximum) or as numbers with percentages in parentheses. Significance, p<0.05. Student's t-test and Fisher's exact test.

The multivariate analysis showed that hypokalemia (OR: 0.7, p = 0.02), dehydration (OR: 2.1, p = 0.006) and metabolic acidosis (OR: 2.3, p = 0.03) were independent risk factors for thrombocytopenia at admission (Table 3). Lengthy disease (OR: 1.2, p = 0.001) and the presence of AKI (OR: 6.6, p = 0.004) were independent risk factors for thrombocytopenia during the hospital stay (Table 4).
Table 3

Independent risk factors for thrombocytopenia in patients with leptospirosis at admission.

OR95% CIp-value
Low potassium level0.70.5-0.90.02
Dehydration2.11.2-3.50.006
Metabolic acidosis2.31.0-5.40.03

OR: odds ratio; 95% CI: 95% confidence interval. Multivariate analysis; chi-square test. Significance, p<0.05.

Table 4

Independent risk factors for thrombocytopenia in patients with leptospirosis during their hospital stay.

OR95% CIp-value
Lengthy disease1.21.0-1.40.001
AKI6.61.8-230.004

OR: odds ratio; 95% CI: 95% confidence interval. Multivariate analysis; chi-square test. Significance, p<0.05.

Death occurred in 22 patients (12.5%) without thrombocytopenia and 25 patients (12.6%) with thrombocytopenia at admission. Mortality was not associated with the presence of thrombocytopenia at hospital admission (12.5% vs. 12.6%, p = 1.000) or during the hospital stay (12.6% vs. 11.3%, p = 0.748). Low DBP (OR: 0.9, p = 0.02), advanced age (OR: 1.0, p = 0.001) and oliguria (OR: 5.4, p = 0.006) were independent risk factors for death (Table 5).
Table 5

Independent risk factors for death in patients with leptospirosis.

OR95% CIp-value
Diastolic blood pressure0.90.8-0.90.02
Advanced age1.01.0-1.10.001
Oliguria5.41.6-180.006

OR: odds ratio; 95% CI: 95% confidence interval. Multivariate analysis; chi-square test. Significance, p<0.05.

DISCUSSION

Hemorrhagic complications contribute to mortality in leptospirosis. Recent studies have shown a direct association between thrombocytopenia and the occurrence of bleeding manifestations 7. In the present study, we evaluated a large number of patients with leptospirosis-associated thrombocytopenia. Most studies on leptospirosis have focused on AKI and pulmonary complications. After several outbreaks of pulmonary hemorrhage in association with leptospirosis, attention has shifted to understanding the mechanism of bleeding diathesis in these patients. Initially, thrombocytopenia in leptospirosis was thought to be mild and rare. However, certain reviews have reported a higher prevalence 12,13. There are several hypotheses about the possible mechanism of this complication: 1) the presence of disseminated intravascular coagulation 12; 2) the participation of cytotoxins 13; and 3) the direct complication of vasculitis, triggered by the Leptospira 14. Further studies are needed to establish the actual pathophysiology of this complication. The independent risk factors for thrombocytopenia were dehydration, metabolic acidosis and low potassium levels at admission. Low serum potassium was a protective factor against thrombocytopenia, i.e., hyperkalemia is associated with thrombocytopenia. This phenomenon may be due to oliguric AKI and metabolic acidosis because there is no cause-effect relationship between serum potassium and the occurrence of thrombocytopenia. Dehydration and metabolic acidosis are systemic manifestations of leptospirosis that are associated with thrombocytopenia. Hemorrhagic manifestations were more frequent in patients in the thrombocytopenia group. Thrombocytopenia was also associated with poor laboratory findings, such as hypoalbuminemia, lower hemoglobin levels and higher AST and total bilirubin levels. However, this condition did not translate into a worse prognosis. In contrast to our study, Spichler et al. 14 reported that elevated creatinine (>3 mg/dL; OR: 4.2) and total bilirubin (>6 mg/dL; OR: 2.2) levels were associated with a lethal outcome. Turgut et al. 15 showed that there was an inverse correlation between ALT/AST levels and thrombocyte counts (r = –0.360; p = 0.016) and that, consistent with our data, there was no statistically significant correlation between bilirubin levels and thrombocytopenia. Certain researchers have reported that a high serum potassium level at hospital admission was an independent risk factor for mortality 16,17. In our study, the overall mortality rate was 12.5%, which is comparable with the rate in other studies 17-23. This large range may be due to the variable severity of the clinical picture, which is partly due to differences between Leptospira strains and the absence of standards for the diagnostic criteria. In the present study, mortality was not associated with the presence of thrombocytopenia. Other studies also showed that mortality was not associated with the presence of thrombocytopenia 16,17, but Spichler et al. 14 showed that it was associated with lethal outcomes, being an independent risk factor for mortality in leptospirosis. Hemorrhagic manifestations are characteristic of Weil's disease and are potentially fatal. Patients can develop important hemodynamic abnormalities secondary to hypovolemia, which is caused by dehydration and the direct effects of Leptospira toxins that damage the vascular endothelium and increase permeability 6. Hemorrhage is recognized as the most important manifestation of human leptospirosis and is being increasingly reported around the world 24. The main hemorrhagic manifestations reported in this study were epistaxis, hemoptysis, hematemesis and hematuria, all of which were more frequent in the patients in the thrombocytopenia group. AKI in leptospirosis is reported in 40-60% of severe cases 25 and is usually non-oliguric 26,27. However, the present study found a higher prevalence (80.5%) according to the RIFLE criteria. There were no differences between the two groups regarding renal function or the need for dialysis. This analysis found that lengthy disease and the presence of AKI were associated with thrombocytopenia during the hospital stay. Regarding antibiotic therapy in leptospirosis, in the present study, penicillin G was administered to 152 (41.6%) of the patients, and there was a tendency toward more frequent use of penicillin among those patients with thrombocytopenia. Thrombocytopenia in leptospirosis is known to be associated with a worse prognosis 9. Tantitanawat and Tanjatham 28 found that platelet counts <100,000/mm3 were an independent risk factor for death in leptospirosis. However, the present study found similar mortality rates in patients with and without thrombocytopenia. A low DBP, advanced age and oliguria were independent risk factors for death. In summary, leptospirosis is a globally relevant disease with a potentially fatal outcome. Hemorrhagic complications are common and are reported as main causes of morbidity and mortality in this disease. Although thrombocytopenia was associated with mortality in previous studies, in the present study, this complication was not a risk factor for death. Advanced age and oliguria were independent risk factors for death.

ACKNOWLEDGMENTS

We are very grateful to the team of physicians, residents, medical students and nurses at the Walter Cantídio University Hospital and the São José Infectious Diseases Hospital for the assistance that they provided to the patients and for the technical support that they provided for the development of this research. This research was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico, CNPq (Brazilian Research Council).
  27 in total

Review 1.  Leptospirosis: a zoonotic disease of global importance.

Authors:  Ajay R Bharti; Jarlath E Nally; Jessica N Ricaldi; Michael A Matthias; Monica M Diaz; Michael A Lovett; Paul N Levett; Robert H Gilman; Michael R Willig; Eduardo Gotuzzo; Joseph M Vinetz
Journal:  Lancet Infect Dis       Date:  2003-12       Impact factor: 25.071

2.  Clinical presentation of leptospirosis: a retrospective study of 201 patients in a metropolitan city of Brazil.

Authors:  Elizabeth F Daher; Rafael Sa Lima; Geraldo B Silva Júnior; Eveline C Silva; Nahme Nn Karbage; Raquel S Kataoka; Paulo C Carvalho Júnior; Max M Magalhães; Rosa Ms Mota; Alexandre B Libório
Journal:  Braz J Infect Dis       Date:  2010 Jan-Feb       Impact factor: 1.949

Review 3.  The globalization of leptospirosis: worldwide incidence trends.

Authors:  Georgios Pappas; Photini Papadimitriou; Vasiliki Siozopoulou; Leonidas Christou; Nikolaos Akritidis
Journal:  Int J Infect Dis       Date:  2007-12-04       Impact factor: 3.623

Review 4.  Pulmonary manifestations of leptospirosis.

Authors:  K M O'Neil; L S Rickman; A A Lazarus
Journal:  Rev Infect Dis       Date:  1991 Jul-Aug

Review 5.  Definition and classification of acute kidney injury.

Authors:  John A Kellum; Rinaldo Bellomo; Claudio Ronco
Journal:  Nephron Clin Pract       Date:  2008-09-18

6.  Leptospirosis: prognostic factors associated with mortality.

Authors:  H Dupont; D Dupont-Perdrizet; J L Perie; S Zehner-Hansen; B Jarrige; J B Daijardin
Journal:  Clin Infect Dis       Date:  1997-09       Impact factor: 9.079

7.  Leptospirosis in Chonbuk Province of Korea in 1987: a study of 93 patients.

Authors:  S K Park; S H Lee; Y K Rhee; S K Kang; K J Kim; M C Kim; K W Kim; W H Chang
Journal:  Am J Trop Med Hyg       Date:  1989-09       Impact factor: 2.345

8.  Coagulation disorders in patients with severe leptospirosis are associated with severe bleeding and mortality.

Authors:  J F P Wagenaar; M G A Goris; D L Partiningrum; B Isbandrio; R A Hartskeerl; D P M Brandjes; J C M Meijers; M H Gasem; E C M van Gorp
Journal:  Trop Med Int Health       Date:  2009-12-09       Impact factor: 2.622

9.  Acute renal failure of leptospirosis: nonoliguric and hypokalemic forms.

Authors:  A C Seguro; A V Lomar; A S Rocha
Journal:  Nephron       Date:  1990       Impact factor: 2.847

10.  Leptospiral nephropathy.

Authors:  Lúcia Andrade; Elizabeth de Francesco Daher; Antonio Carlos Seguro
Journal:  Semin Nephrol       Date:  2008-07       Impact factor: 5.299

View more
  11 in total

1.  Weil's disease with haemoptysis and acute respiratory distress syndrome.

Authors:  Afroditi Roumpou; Ioanna Papaioannou; Christos Lampropoulos
Journal:  BMJ Case Rep       Date:  2019-05-30

2.  Serial Changes in Complete Blood Counts in Patients with Leptospirosis: Our Experience.

Authors:  Deepa Sowkur Anandarama Adiga; Salony Mittal; Harini Venugopal; Sowmya Mittal
Journal:  J Clin Diagn Res       Date:  2017-05-01

3.  Pediatric Fulminant Leptospirosis Complicated by Pericardial Tamponade, Macrophage Activation Syndrome and Sclerosing Cholangitis.

Authors:  Osman Yeşilbaş; Hasan Serdar Kıhtır; Hamdi Murat Yıldırım; Nevin Hatipoğlu; Esra Şevketoğlu
Journal:  Balkan Med J       Date:  2016-09-01       Impact factor: 2.021

4.  Predictors of lethality in severe leptospirosis in Transcarpathian region of Ukraine.

Authors:  Pavlo Petakh; Andriy Nykyforuk
Journal:  Infez Med       Date:  2022-06-01

5.  The Applicability of Commonly Used Severity of Illness Scores to Tropical Infections in Australia.

Authors:  Kris Salaveria; Simon Smith; Yu-Hsuan Liu; Richard Bagshaw; Markus Ott; Alexandra Stewart; Matthew Law; Angus Carter; Josh Hanson
Journal:  Am J Trop Med Hyg       Date:  2021-10-18       Impact factor: 3.707

6.  Pancreatitis as a severe complication of leptospirosis with fatal outcome: a case report.

Authors:  Pedro Eduardo Andrade de Carvalho Gomes; Sávio de Oliveira Brilhante; Rachel Bezerra Carvalho; Daniel Ribeiro de Sousa; Elizabeth De Francesco Daher
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2019-12-20       Impact factor: 1.846

7.  Importance of KIM-1 and MCP-1 in Determining the Leptospirosis-Associated AKI: A Sri Lankan Study.

Authors:  Thilini Nisansala; Manjula Weerasekera; Nilantha Ranasinghe; Chamil Marasinghe; Chandika Gamage; Neluka Fernando; Chinthika Gunasekara
Journal:  Biomed Res Int       Date:  2021-06-02       Impact factor: 3.411

8.  Risk factors for intensive care unit admission in patients with severe leptospirosis: a comparative study according to patients' severity.

Authors:  Elizabeth De Francesco Daher; Douglas Sousa Soares; Anna Tereza Bezerra de Menezes Fernandes; Marília Maria Vasconcelos Girão; Pedro Randal Sidrim; Eanes Delgado Barros Pereira; Natalia Albuquerque Rocha; Geraldo Bezerra da Silva
Journal:  BMC Infect Dis       Date:  2016-02-01       Impact factor: 3.090

Review 9.  Phagocyte Escape of Leptospira: The Role of TLRs and NLRs.

Authors:  Ignacio Santecchia; María Florencia Ferrer; Monica Larucci Vieira; Ricardo Martín Gómez; Catherine Werts
Journal:  Front Immunol       Date:  2020-10-06       Impact factor: 7.561

10.  Acute kidney injury in dogs: Etiology, clinical and clinicopathologic findings, prognostic markers, and outcome.

Authors:  Dar Rimer; Hilla Chen; Mali Bar-Nathan; Gilad Segev
Journal:  J Vet Intern Med       Date:  2022-02-01       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.